Trial Profile
A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2016
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Feb 2016 New trial record